New: NCI-funded clinical trial search
Mednet Logo
CommunityPrimary Care

What oral alternatives would you recommend as opposed to injectable GnRH agonists for those who do not wish to come to clinic due to COVID-19?

This applies to both de novo cases and patients who have previously received injectable agents.
1 Answer
Mednet Member
Mednet Member
Radiation Oncology · Prostate Cancer Institute of America
Answered on · Updated on

Casodex is an option. Due to liver toxicity, they would need LFTs checked before and at a future interval, effectively requiring them 3 visits to a health care facility—labs, pharmacy, labs. A single 6 month injection seems like a better proposition.

Join for free or sign in to see the full answer